Cardioprotective effects of nicorandil in patients undergoing on-pump coronary artery bypass surgery.
OBJECTIVE
The purpose of this study was to assess the cardioprotective effects of nicorandil in patients undergoing coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass (CPB).


METHODS
A prospective, double-blind, randomized clinical study.


METHODS
A university hospital.


METHODS
Thirty-two patients undergoing elective CABG surgery.


METHODS
Patients were randomized into 2 groups: the nicorandil and placebo groups. In the nicorandil group, intravenous nicorandil infusion was started after the induction of anesthesia by a loading dose of 0.1 mg/kg, followed by a continuous infusion of 0.1 mg/kg/h until 2 hours after CPB, then decreased to 0.05 mg/kg/h, and discontinued at the end of surgery. The placebo group received the same volume of saline. Arterial blood was sampled, and serum troponin T (TnT) and CK-MB were measured at the following 4 stages: after the induction of anesthesia (baseline), 2 hours after CPB, the first postoperative day (POD), and the third POD.


RESULTS
TnT concentrations were similar at baseline and increased with a peak on the first POD in both groups. In the nicorandil group, TnT concentration returned to the baseline value at the third POD, and the time course of TnT showed significantly lower levels (p = 0.012). CK-MB concentrations were similar at baseline, increased and peaked at 2 hours after CPB, and returned to the baseline on the third POD in both groups. There were no significant differences between the groups with respect to the changes in CK-MB concentrations.


CONCLUSIONS
The nicorandil group showed lower concentrations of TnT, suggesting that intraoperative administration of nicorandil may provide a degree of myocardial protection in CABG surgery.
Yamamoto
Shinichi
S
Department of Anesthesiology, School of Medicine, Keio University, Tokyo, Japan. y-sinn@fg8.so-net.ne.jp
Yamada
Tatsuya
T
Kotake
Yoshifumi
Y
Takeda
Junzo
J
D000368:Aged; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020108:Nicorandil / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000209:etiology / Q000517:prevention & control; D011446:Prospective Studies
D002316:Cardiotonic Agents; D020108:Nicorandil